Results 171 to 180 of about 171,681 (303)
Radiation emergency medical countermeasures: Current formulary, identified gaps, and future approaches
Animal Models and Experimental Medicine, EarlyView.Current radiation medical countermeasures primarily focus on hematopoietic acute radiation syndrome (H‐ARS) using agents like granulocyte colony‐stimulating factor (G‐CSF), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and romiplostim, alongside treatments for internal contamination (Prussian blue, diethylenetriamine pentaacetate [DTPA ...Wen‐Bing Ma, Rong‐Hua Yin, Guang‐Ming Ren, Yin Zhang, Li‐Juan Li, Wei Liu, Ting Chen, Wei Zhou, Mian Zu, Rong‐Ling Yin, Xin‐Di Shi, Lei Wang, Xiao‐Ming Yang +12 morewiley +1 more sourceConclusions of the 2nd Croatian symposium „Disaster medicine“. II. Military-civilian or civil-military cooperation
Kevrić, Šime, Svetina, Lucija, Vukić, Veljko, Pavić-Kevrić, Ružica, Herceg, Maja, Cvitanović, Hrvoje, Žunić, Josip +6 moreopenalex +1 more sourceAssociation between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease
Annals of Neurology, EarlyView.Objective
Lewy body disease (LBD) is a complex neurodegenerative disorder characterized by the accumulation of misfolded α‐synuclein in the brain. Neuroinflammation has long been implicated in LBD pathogenesis, and recent genetic studies in Parkinson's disease (a clinical manifestation of LBD) have shown consistent association with the human leukocyte ...Marios Gavrielatos, Michael G. Heckman, Alexandra I. Soto‐Beasley, Sophia G. Blumenfeld, Xu Hou, Shunsuke Koga, Melissa E. Murray, Koji Kasanuki, Daisuke Ono, Fabienne C. Fiesel, Ryan J. Uitti, Julie A. Fields, Hugo Botha, Vijay K. Ramanan, Kejal Kantarci, Val J. Lowe, Clifford R. Jack, Nilufer Ertekin‐Taner, J. Raphael Gibbs, Bryan J. Traynor, Clifton L. Dalgard, Rodolfo Savica, Jonathan Graff‐Radford, Ronald C. Petersen, R. Ross Reichard, Neill R. Graff‐Radford, Tanis J. Ferman, Bradley F. Boeve, Zbigniew K. Wszolek, Wolfdieter Springer, Ziv Gan‐Or, Emmanuel Mignot, Sonja W. Scholz, Dennis W. Dickson, Owen A. Ross +34 morewiley +1 more sourceAneurysm Wall Enhancement and Probability of Instability in Unruptured Intracranial Aneurysms: A Long‐Term Follow‐Up Study
Annals of Neurology, EarlyView.Objective
Aneurysm wall enhancement (AWE) may predict aneurysm growth and rupture in the short‐term, but there is a lack of long‐term follow‐up studies. We aimed to determine whether unruptured intracranial aneurysms (UIAs) with AWE have a higher probability of aneurysm instability during long‐term follow‐up compared with those without AWE. Methods
For Laura T. van der Kamp, Maarten J. Kamphuis, Olivier Naggara, Thomas Le Tat, Gabriel J. E. Rinkel, Gérard A. P. de Kort, Ruben P. A. van Eijk, Jeroen Hendrikse, Irene C. van der Schaaf, Mervyn D. I. Vergouwen +9 morewiley +1 more sourceAmerican College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Arthritis &Rheumatology, EarlyView.Objective
Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heilblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson +111 morewiley +1 more sourceA Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Arthritis &Rheumatology, EarlyView.Objective
Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp +14 morewiley +1 more source
